TOKYO, Apr 09 (Pulse News Wire) – Wolves Hand Co., Ltd. (194A.T) announced today that it has established a new research consortium with external animal hospitals and veterinarians focused on anti-aging studies using animal stem cell culture supernatants in regenerative medicine.
The decision was made during a management meeting held. Since last year, Wolves Hand has been conducting clinical trials in collaboration with First Class Corporation (headquartered in Tokyo, Minato Ku, led by Norimasa Nomura). Preliminary results show significant improvements in activity levels among 21 out of 22 dogs treated with sheep amniotic-derived stem cell culture supernatant (SC-CM). Additional benefits such as improved coat luster, appetite, and lung capacity have also been observed.
These findings were presented at the 68th Comparative Integrated Medical Science Academic Conference in Tokyo on November 9, 2025, earning the prestigious President's Award. However, there remains a lack of clear regulatory guidelines for regenerative medicine in veterinary practice, similar to those governing human applications. As discussions around revising laws to ensure safety continue, Wolves Hand aims to contribute to enhancing pet quality of life and creating new therapeutic value in animal healthcare through its ongoing research efforts. Participating animal hospitals in the consortium include Maneki Neko Hospital (Osaka Prefecture), Shinjo Animal Hospital (Nara Prefecture), Alice Animal Clinic (Saitama Prefecture), Aipet Animal Hospital (Chiba Prefecture), and Sasukenn Cat and Dog Hospital (Tochigi Prefecture).
The company stated that the impact of this initiative on its performance is expected to be minor.
🟢 Confidence: High AI-translated content.